New drug combo aims to outsmart resistant lung cancer

NCT ID NCT07322783

Recruiting now Disease control Sponsor: Qingdao Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding savolitinib to osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) that has become resistant to osimertinib. The study enrolls 60 adults whose tumors have low levels of MET amplification. Participants take both drugs daily until the disease worsens or side effects become too severe. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib and savolitinib (two cancer drugs taken as pills)
What this could lead to: If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard therapy.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR POSITIVE NON-SMALL CELL LUNG CANCER MET AMPLIFICATION

Contacts and locations

Locations

Qingdao Central Hospital
RECRUITING

Qingdao, 266042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.